Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
IDEAYA Biosciences, Inc. (IDYA) had Consolidated Net Income/Loss of $-98.54M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$6.56M |
|
$-98.54M |
|
-- |
|
$6.56M |
|
$115.10M |
|
$-108.54M |
|
$10.01M |
|
$-98.54M |
|
$-98.54M |
|
$-98.54M |
|
$-98.54M |
|
|
Consolidated Net Income/Loss |
$-98.54M |
$-98.54M |
|
$-108.54M |
|
$-108.61M |
|
88.70M |
|
88.70M |
|
$-1.11 |
|
$-1.11 |
|
| Balance Sheet Financials | |
$696.11M |
|
$8.63M |
|
$334.24M |
|
$1.03B |
|
$64.83M |
|
-- |
|
$28.25M |
|
$93.08M |
|
$937.27M |
|
$937.27M |
|
$937.27M |
|
87.86M |
|
| Cash Flow Statement Financials | |
$-75.17M |
|
$118.95M |
|
$1.18M |
|
$113.84M |
|
$158.80M |
|
$44.96M |
|
$14.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.74 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1654.63% |
|
-1654.63% |
|
-- |
|
-1502.12% |
|
-1502.12% |
|
$-76.14M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-10.51% |
|
-10.51% |
|
-9.56% |
|
-10.51% |
|
$10.67 |
|
$-0.86 |
|
$-0.85 |
|